Leqvio was launched in the United States on December 16, 2020 [1]. The U.S. Food and Drug Administration (FDA) approved Leqvio in December 2020 [1].
How long does Leqvio's patent protection last?
Information regarding Leqvio's specific patent expiry dates is available through resources like DrugPatentWatch.com [2]. These patents typically extend market exclusivity for the drug, affecting when generic versions can enter the market [2].
What is Leqvio used to treat?
Leqvio is prescribed to treat adults with high cholesterol. Specifically, it is used in conjunction with diet and maximally tolerated statin therapy to lower low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) [3].
How does Leqvio work?
Leqvio is an siRNA-based therapy that works by reducing the production of PCSK9 protein in the liver [3]. PCSK9 normally limits the number of LDL receptors available to clear LDL-C from the blood. By lowering PCSK9, Leqvio increases the number of LDL receptors, leading to more LDL-C being cleared from the bloodstream [3].
Who makes Leqvio?
Leqvio is manufactured by Novartis [3].
What are the potential side effects of Leqvio?
Common side effects reported with Leqvio include injection site reactions, upper respiratory tract infections, and muscle pain [3].